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pemetrexed arm compared to 0.62 for the gemcitabine arm. The total cost per patient 
was a20,438 for pemetrexed/cisplatin and a17,605 for gemcitabine/cisplatin. These 
model outputs result in incremental cost-effectiveness ratios of a24,507 per LYG, and 
a48,666 per QALY gained. Univariate sensitivity analyses show that the results are 
most sensitive to overall survival. CONCLUSIONS: For oncolytics in Italy, a70,000/
QALY is often considered a good indication of willingness-to-pay threshold. Accord-
ing to the model, pemetrexed/cisplatin is a cost-effective alternative to gemcitabine/
cisplatin in the ﬁrst-line treatment of NSCLC patients within the adenocarcinoma 
population.
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OBJECTIVES: A multicenter randomized phase III trial (study 304820) showed 
patients with stage III or IV follicular lymphoma who achieved a partial or complete 
response after ﬁrst-line treatment wtih 90Y-ibritumomab tiuxetan had signiﬁcantly 
longer PFS time than patients receiving no treatment. The objective of this study is to 
compare costs and outcomes of subsequent treatment with a course of 90Y-ibritu-
momab tiuxetan compared with no treatment in patients with complete or partial 
response following ﬁrst-line chemotherapy from a Spanish payer perspective.
METHODS: A lifetime Markov model was developed to compare 90Y-ibritumomab 
tiuxetan consolidation therapy vs. ‘no consolidation’. The model consists of four 
states: progression-free with complete response (CR), progression-free with partial 
response (PR), progressive disease and death. Patients enter the model after an assess-
ment of response to ﬁrst-line treatment (induction therapy) demonstrates partial or 
complete response. An important feature of the model is the possibility for response 
status to convert from PR to CR as shown in study 304,820. Following ﬁnal response, 
individuals either remain in their current health state, experience disease progression, 
or die. PFS data from the trial was used to model disease progression. Costs were 
calculated from the perspective of the Spanish health care system. Future costs and 
beneﬁts were discounted at 3.5% per annum. Utilities were calculated using the EQ-
5D from study 304,820. RESULTS: The incremental cost per additional QALY is 
estimated to be a18,263 for partial responders and a29,322 for all responders (includ-
ing those with a complete response after ﬁrst-line therapy). The parameters which 
have the greatest impact are the utility estimates, particularly the utility in the progres-
sion-free health state. CONCLUSIONS: The base case model demonstrates that 90Y-
ibritumomab tiuxetan consolidation following induction therapy offers good value for 
money while signiﬁcantly prolonging PFS. Sensitivity analyses show the results to be 
reasonably robust.
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OBJECTIVES: The 76 months follow-up of the BIG 1-98 study reported a hazard 
ratio [HR] for overall survival (OS) of 0.81 and a HR for disease free survival (DFS) 
of 0.84 in the letrozole (LET) group versus tamoxifene (TAM). The 100 months   
follow-up of the ATAC study reported almost identical results observed at 68 months 
follow-up for the HR of OS (0,97) in the anastrozole (ANA) group when compared 
with TAM. The HR for DFS was 0.85. This analysis compares the cost-effectiveness 
of LET and ANA versus tamoxifen from the Canadian health care perspective using 
the most recent survival data from the BIG 1-98 and ATAC studies. METHODS: A 
Markov model was used to estimate the cost per quality adjusted life year (QALY) of 
LET or ANA versus TAM. Annual survival probabilities were extracted from updated 
BIG 1-98 and ATAC trials, and literature. Cost values representing resource use were 
informed by a Canadian costing analysis. Utility weights were derived from literature. 
A time horizon of 20 years and a 5% discount rate were used. RESULTS: LET and 
ANA are predicted to increase QALYs by 0.26 and 0.05 per patient compared to 
TAM, respectively. Lifetime costs increase by $2710 and $2297 for LET and ANA 
respectively. The incremental cost-effectiveness ratio (ICER) of LET versus TAM is 
$10,420. The ICER for ANA versus TAM is $41,569. The model is more sensitive to 
the variation of the hazard ratios for overall survival. The probability that LET and 
ANA are cost-effective given a threshold value of 50,000 per QALY is 99% for LET 
and 58% for ANA. CONCLUSIONS: Our model shows that LET has a substantially 
lower expected ICER of $10,420 compared to ANA, with mean ICER of $41,569 
over a 20 year time horizon from the Canadian health care perspective.
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OBJECTIVES: Several new interventions have become available recently for the 
 adjuvant treatment of early breast cancer (EBC) which are effective in reducing 
the incidence of disease relapse. Our objective was to develop a model to evaluate the 
cost-effectiveness and cost-utility of such interventions in the USA. The model was 
demonstrated for the comparison of docetaxel (75 mg/m2), doxorubicin (50 mg/m2), 
and cyclophosphamide (500 mg/m2) (TAC, 6 cycles) with ﬂuorouracil (500 mg/m2), 
doxorubicin (50 mg/m2), and cyclophosphamide (500 mg/m2) (FAC, 6 cycles) in node-
positive EBC patients. METHODS: A combined decision tree and Markov model 
estimated costs and outcomes from initiation of adjuvant chemotherapy to death. 
Parametric survival functions were ﬁtted to patient-level data from trial BCIRG 001 
and time-dependent transition probabilities for disease relapse were estimated. Costs 
were estimated from US databases (Pharmetrics claims database and Premier hospital 
database) and a published retrospective analysis of linked SEER-Medicare data for 
1580 EBC patients with disease recurrence (cost year 2008). Utility weights were 
estimated from EORTC QLQ-C30 data collected in trial BCIRG 001 using a published 
algorithm, and from published literature. Probabilistic and univariate sensitivity analy-
sis (varying all parameters by / 50% of base-case values) were performed. Alterna-
tive scenarios were programmed to explore uncertainty beyond the trial follow-up 
period. RESULTS: Mean total expected lifetime costs and outcomes were signiﬁcantly 
higher for the TAC cohort. Incremental costs were $19,732 (95% CIs $15,869–
$31,441); life years were 0.93 (0.87–0.97) and QALYs were 0.74 (0.44–0.91). Incre-
mental cost-effectiveness ratios for TAC versus FAC were $21,318 per life year saved 
($16,953–$33,856) and $26,654 per QALY ($18,553–$50,554). In univariate sensi-
tivity analysis, results were most sensitive to the utility weight for remission post-
chemotherapy. The incremental cost per QALY remained below $50,000 for all 
plausible parameter estimates, and all extrapolation scenarios. CONCLUSIONS: The 
model provides a robust framework for estimating cost-effectiveness, allowing explo-
ration of critical areas of uncertainty.
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OBJECTIVES: To calculate the cost effectiveness of the addition of cetuximab to 
chemotherapy to enable resection of liver metastases in 1st-line metastatic colorectal 
cancer (mCRC) from the UK NHS perspective. METHODS: Cetuximab is licensed 
for the treatment of mCRC in combination with standard chemotherapy (FOLFIRI 
and FOLFOX) in patients with wildtype KRAS and EGFR expressing tumours. A semi 
Markov model was developed to simulate patient outcomes and costs throughout ﬁrst 
and subsequent lines of treatment including long-term survival after a successful cura-
tive resection of liver metastases. Data for model parameters were mainly derived the 
CRYSTAL and OPUS studies. The potential for curative-intent liver surgery was esti-
mated using resection rates from CELIM and Tournigand et al for cetuximab arms 
and chemotherapy arms respectively. The long-term beneﬁts of surgery were estimated 
from Adam et al. Extensive scenario and probabilistic sensitivity analyses were under-
taken to explore the robustness of the results with regard to various modelling 
assumptions and model parameter uncertainty. RESULTS: In the base case the addi-
tion of cetuximab to FOLFIRI/FOLFOX resulted in additional QALYs of 0.78 and 
0.59 and incremental cost effectiveness ratios (ICERs) of £19,557 and £21,056 per 
QALY respectively. The ICER is mainly driven by the number of patients becoming 
resectable, the acquisition cost of cetuximab, and choice of parametric model for 
progression-free survival curves. CONCLUSIONS: The analysis demonstrates that 
cetuximab is a cost-effective 1st line treatment option for patients with EGFR express-
ing, KRAS wildtype colorectal cancer, for patients whose liver metastases have been 
rendered resectable by cetuximab and. chemotherapy. This analysis resulted in positive 
draft guidance by NICE on June 1, 2009. Final Guidance will be posted on the NICE 
website in July 2009.
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OBJECTIVES: Approximately 8.33 years of randomized clinical trial data is now 
available from the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial, 
conﬁrming that the advantage of anastrozole in recurrence free survival compared 
with tamoxifen in hormone receptor-positive (HR) postmenopausal (PM) early breast 
cancer (EBC) patients is preserved even after stopping treatment at 5 years. Using the 
long-term outcome data, this study estimated the cost-utility of anastrozole versus 
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tamoxifen from a German health service perspective. METHODS: A semi-Markov 
model was adapted to include the 100-month clinical trial efﬁcacy data. Kaplan-Meier 
curves on time to recurrence (TTR) from the ATAC trial were ﬁtted by survival regres-
sion including a treatment coefﬁcient. Treatment speciﬁc progression rates were 
extrapolated to 10 years, and were assumed equivalent based on pooled treatment 
arms thereafter. Survival probabilities after recurrence were identical for all treat-
ments, based on German national mortality data. Published literature and physician 
survey provided data on resource use and unit costs and utilities. Probabilistic analysis 
was carried out to obtain incremental cost-effectiveness ratios and cost-effectiveness 
acceptability curves. Sensitivity analyses were conducted. RESULTS: Over 25 years 
anastrozole patients gained 0.32 QALYs at a cost of a6,819 per patient, resulting in 
an ICER of a21,069 (95%CI: a12,567–a46,604) per QALY gained, vs tamoxifen. 
With a 90% probability the ICER was below a30,000/QALY. The results were 
robust to plausible changes in parameters tested in sensitivity analyses, including the 
hazard ratio for TTR. CONCLUSIONS: This is the ﬁrst cost-utility analysis of an 
aromatase inhibitor based on extended follow-up data. Anastrozole’s carryover 
treatment effect beyond therapy completion at 5 years translates into favourable 
cost-effectiveness results against tamoxifen for PM HR EBC women from a German 
national health insurance perspective.
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OBJECTIVES: To evaluate cost-utility of docetaxel (75 mg/m2 every 3 weeks) com-
pared with best supportive care (BSC) or pemetrexed (500 mg/m2 every 3 weeks) as 
second-line therapy in advanced non-small cell lung cancer in the Polish setting. 
METHODS: A cost-utility approach was adopted, evaluating total direct costs 
incurred by the Polish National Health Fund (NHF), life years gained (LYG) and 
quality-adjusted life years (QALY). A micro-simulation Markov model was used to 
estimate utilities and costs of treatment. The ﬁrst course of chemotherapy was assumed 
as the starting-time point of the model. Simulation was terminated at the time of the 
patient’s death or after two years following start of the treatment. It was assumed that 
patients would undergo 4 cycles of chemotherapy or less if progression occurred 
during treatment. In case of progression of disease chemotherapy would be terminated 
and patients would receive palliative care until death. Transition probabilities between 
health states were calculated based on a systematic review of RCTs. Health states 
utilities were taken from published literature. Costs were taken from NHF catalogue. 
Probabilistic sensitivity analysis was performed in order to estimate the probability 
that docetaxel was cost effective in Polish settings where threshold is about 91,000 
polish zloty (PLN). RESULTS: Incremental costs for docetaxel compared with BSC 
was PLN57,498 per LYG and PLN105,956 per QALY. In 2-years time horizon 
docetaxel was PLN13,582 less costly than pemetrexed (CI95%: 8,224; 17,704). The 
probability of docetaxel cost effectiveness over BSC was 99.71% for LYG and 10.11% 
for QALY. The probability of docetaxel cost effectiveness over pemetrexed was 
99.78% for LYG and 100% for QALY. CONCLUSIONS: Docetaxel seems to be cost 
effective in comparison with BSC and pemetrexed in the Polish setting.
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OBJECTIVES: More than one million new cases of colorectal cancer are diagnosed 
worldwide annually. In Ireland, incidence rates are among the highest in western 
Europe, survival is lower than the European average, and mortality in men exceeds 
that in other western European countries. We evaluated the cost-effectiveness of a 
population-based colorectal cancer screening programme in Ireland. METHODS: 
Three screening scenarios were assessed: 1) biennial guaiac-based faecal occult blood 
testing (gFOBT) in those aged 55–74; 2) biennial faecal immunochemical testing (FIT) 
in those aged 55–74; and 3) once-only ﬂexible sigmoidoscopy (FSIG) at age 60. A 
Markov model was used to followed a cohort of 55-year-old individuals over their 
lifetime. Model parameters were obtained from local data, literature review and expert 
clinical opinion. Costs included screening and diagnostic tests, cancer treatment, 
complications, and surveillance of screen-detected adenomas. Health outcomes were 
assessed in quality-adjusted life years (QALYs). Costs and outcomes were discounted 
at 4% per annum. Screening scenarios were compared with the status quo (“no screen-
ing”). Probabilistic sensitivity analyses were undertaken. RESULTS: All three screen-
ing scenarios were highly cost-effective compared to no screening. In the base-case 
analysis, FSIG had the lowest incremental cost-effectiveness ratio (ICER  a589 per 
QALY gained), followed by FIT (a1,696 per QALY gained), and gFOBT (a4428 per 
QALY gained). gFOBT was dominated. Compared to FSIG, FIT was associated with 
a greater health gain, and greater lifetime reductions in colorectal cancer incidence 
(15%) and mortality (36%). However, it was more costly than FSIG, required more 
colonoscopies, and would result in more complications. The ICER for FIT versus FSIG 
was a2058 per QALY gained. Results were robust to variations in parameter esti-
mates. CONCLUSIONS: These results suggest that population-based colorectal cancer 
screening would be a highly cost-effective in Ireland. FIT is the optimal screening 
strategy since it as associated with the greatest health gain.
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OBJECTIVES: Prostatic cancer is the second most frequent cancer and the third 
highest cause of cancer-related deaths in Italy. Age is the principal risk factor and 
given the ageing Italian population, it seems that the related health care expenditure 
is bound to increase, causing the need for pharmacoeconomic evaluation of therapies 
available. METHODS: We performed a cost/utility analysis using a Markov model of 
hormonal therapies in patients with advanced prostate cancer who underwent radical 
prostatectomy, from biochemical recurrence to death. Nine androgen suppression 
therapies were considered: orchiectomy, two nonsteroidal antiandrogens (NSAA), four 
luteinising hormone-releasing hormone (LHRH) agonists, cyproterone acetate and the 
maximal androgen blockade (MAB) obtained with the association of a NSAA and a 
LHRH. In the simulation, the androgen suppression therapies were started at PSA 
recurrence and continued until death. The model used the Italian NHS prospective 
and a patient’s lifetime simulation horizon. Drug costs were calculated for each 
therapy, considering the less costly brand. RESULTS: All therapies produced a life 
expectancy (LE) of about 12 life years (LYs) with a small variability ranging from 
12.3 LYs for MAB to 11.37 LYs for NSAA-ﬂutamide. Quality adjusted life expectancy 
ranged from 9.98 QALYs for MAB to 9.28 QALYs for NSAA-ﬂutamide. The cost per 
patient presented more variability, from a12,538 for orchiectomy to a59,496 for 
NSAA-bicalutamide. Orchiectomy provided the most cost/effective alternative with 
a1300/QALY. In the LHRH-agonists class leuprorelin was the most cost/effective at 
about a2200/QALY. CONCLUSIONS: MAB was identiﬁed as the most effective and 
the most costly therapy. Orchiectomy was less effective but involved the lowest cost 
and, thus, represented the most cost/effective strategy. Nonetheless, its application in 
actual clinical practice is difﬁcult and it is almost always refused by patients. Among 
the class of LHRH-agonists, leuprorelin (22.5 mg–7.5 mg) dominated the alternatives 
and provided an excellent therapeutic strategy.
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OBJECTIVES: At a median follow-up of 100 months in the ATAC trial, anastrozole 
demonstrated signiﬁcant improvements compared with tamoxifen in disease-free sur-
vival (HR: 0.85, p  0.003) and time-to recurrence (TTR) (HR: 0.76, p  0.0001). 
Absolute difference in TTR increased over time, 2.8% at 5 years and 4.8% at 9 years. 
Recurrence rates remained signiﬁcantly lower on anastrozole after treatment comple-
tion. This study assesses the long-term cost-effectiveness of adjuvant treatment 
with anastrozole versus tamoxifen in women with early breast cancer in Sweden. 
METHODS: A Markov model was developed to integrate trial data with external 
data on costs and quality of life speciﬁc for Swedish breast cancer patients. The model 
adopts a life-long perspective and the primary outcome measure was QALYs. In the 
base-case model, TTR for tamoxifen and anastrozole diverge out to 10 years. Mortal-
ity risks for recurred and non-recurred patients are based upon trial data and national 
statistics. Resource utilization and utility estimates were based on Swedish data for 
patients in different stages of breast cancer. Utility weights were estimated with EQ-
5D. All costs and beneﬁts were discounted at 3% at 2005-year prices. RESULTS: 
In base-case, patients treated with anastrozole had a higher lifetime expected mean 
cost of SEK 16,000 compared to patients on tamoxifen, and gained on average 0.11 
QALYs per patient. This corresponds to an incremental cost of approximately SEK 
145,000 per QALY gained. CONCLUSIONS: This updated cost-effectiveness analysis 
of the ATAC trial is conservative, neither is any assumption made of an accrued sur-
vival beneﬁt due to a signiﬁcantly lower recurrence rate, nor does the analysis consider 
the potential reduction of costs associated with anastrozole patent expiry. Neverthe-
less, the study demonstrates that up-front anastrozole treatment for ﬁve years is a 
cost-effective option compared to ﬁve years tamoxifen treatment in the lifetime per-
spective for hormone receptor-positive patients.
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OBJECTIVES: The Brazilian guideline for the treatment of CML is not clear whether 
to increase imatinib dosage or switch to dasatinib for imatinib-resistant patients. The 
aim of this study was to evaluate the value of dasatinib versus imatinib 400 mg for 
treatment of imatinib-resistant CML patients (dasatinib 100 mg vs. imatinib 600 mg 
for CP and dasatinib 140 mg vs. imatinib 800 mg for AP and BP), from the Brazilian 
